About
Titles
Associate Professor of Pathology
Director of Quality and Patient Safety, Pathology
Biography
Dr. Gibson received her dual MD and PhD degrees at Mayo Medical School in Rochester, MN in 2004. She completed residency in anatomic and clinical pathology at Brigham and Women's Hospital in Boston, MA in 2008, where she also completed a fellowship in gastrointestinal and liver pathology in 2009. Dr. Gibson joined the Yale Pathology Faculty in August of 2011.
Appointments
Pathology
Associate Professor on TermPrimary
Other Departments & Organizations
- Gastrointestinal (GI) & Liver Pathology
- Hepatic Arterial Infusion (HAI) Program
- Hyperthermic intraperitoneal chemotherapy (HIPEC) Program
- Molecular & Genomic Pathology
- Oligometastatic Cancer Program
- Pancreatic Diseases Program
- Pathology
- Pathology and Molecular Medicine
- Surgical Pathology
- Yale Medicine
- Yale Ventures
Education & Training
- Fellowship
- Brigham & Women's Hospital (2009)
- Residency
- Brigham & Women's Hospital (2008)
- PhD
- Mayo Clinic College of Medicine (2004)
- MD
- Mayo Clinic College of Medicine (2004)
Research
Publications
2024
Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms.
Uhlig J, Nie J, Gibson J, Cecchini M, Stein S, Lacy J, Kunz P, Kim HS. Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms. Sci Rep 2024, 14: 30536. PMID: 39690170, DOI: 10.1038/s41598-024-81518-4.Peer-Reviewed Original ResearchMismatch Repair Proficient Colorectal Adenocarcinoma in Two Patients With Lynch Syndrome.
Khandakar B, Lacy J, Gibson JA. Mismatch Repair Proficient Colorectal Adenocarcinoma in Two Patients With Lynch Syndrome. Clin Genet 2024 PMID: 39660603, DOI: 10.1111/cge.14670.Peer-Reviewed Original ResearchModern Management of Gastric Neuroendocrine Neoplasms
Kunstman J, Nagar A, Gibson J, Kunz P. Modern Management of Gastric Neuroendocrine Neoplasms. Current Treatment Options In Oncology 2024, 25: 1137-1152. PMID: 39083164, DOI: 10.1007/s11864-024-01207-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsG-NENsGastrin-secreting tumorsSurgical resectionHeterogeneous group of tumorsProton pump inhibitor usageResection of visible lesionsG-NEN patientsGroup of tumorsRisk of progressionHigh-risk lesionsMetastatic diseaseNeuroendocrine tumorsNeuroendocrine neoplasmsMetastatic spreadEndoscopic resectionEndoscopic surveillanceTreatment paradigmInhibitor usageNeuroendocrine diseaseResectionTumorLow riskVisible lesionsHeterogeneous groupDe-escalationGrowth characteristics of HCT116 xenografts lacking asparagine synthetase vary according to sex
Aladelokun O, Lu L, Zheng J, Yan H, Jain A, Gibson J, Khan S, Johnson C. Growth characteristics of HCT116 xenografts lacking asparagine synthetase vary according to sex. Human Genomics 2024, 18: 67. PMID: 38886847, PMCID: PMC11184737, DOI: 10.1186/s40246-024-00635-3.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAspartate-Ammonia LigaseCarbon-Nitrogen Ligases with Glutamine as Amide-N-DonorCell ProliferationColorectal NeoplasmsFemaleGene Expression Regulation, NeoplasticHCT116 CellsHeterograftsHumansMaleMiceReceptors, EstrogenReceptors, G-Protein-CoupledSex FactorsXenograft Model Antitumor AssaysConceptsFemale tumor-bearing miceFemale CRC patientsTumor-bearing miceCRC patientsTumor growthInferior survivalAssociated with inferior survivalMetabolic reprogrammingG protein-coupled estrogen receptorTriggering metabolic reprogrammingSustained tumor growthSuppressed tumor growthExpression of asparagine synthetaseCancer cell linesBackgroundSex-related differencesSurvival improvementImpact of sexFemale miceEstrogen receptorCancer growthTranslational relevanceRewiring of metabolic pathwaysCancer burdenMetabolic pathwaysAsparagine synthetase
2022
Systems approach to enhance Lynch syndrome diagnosis through tumour testing
Singh V, Mezzacappa C, Gershkovich P, Di Giovanna J, Ganzak A, Gibson J, Sinard J, Xicola RM, Llor X. Systems approach to enhance Lynch syndrome diagnosis through tumour testing. Journal Of Medical Genetics 2022, 60: 533-539. PMID: 36115663, PMCID: PMC10020126, DOI: 10.1136/jmg-2022-108770.Peer-Reviewed Original ResearchConceptsOriginal cohortColorectal adenocarcinomaLynch syndromeTumor testingGenetic testingPercentage of patientsProportion of patientsLynch syndrome diagnosisCG evaluationCancer genetic testingRace/ethnicityCRC testingCohort studyMMR immunohistochemistryLS diagnosisNew diagnosisMMR lossAcademic centersPatientsSyndrome diagnosisCohortCase identificationMethylation testingReferral differencesReferral mechanismsTu1100: HETEROZYGOUS MUTATIONS IN DNA REPAIR GENES CONFER GENETIC SUSCEPTIILITY TO COLORECTAL CANCER AMONG LYNCH-LIKE CASES
Giner-Calabuig M, De Leon S, Vidal-Pedrola G, Fehlmann T, Ukaegbu C, Gibson J, Picó M, Alenda C, Reyes J, Ortega S, LLado C, de la Torre Rubio P, Obrador-Hevia A, Castillejo A, Soto J, Castellví-Bel S, Syngal S, Stoffel E, Ellis N, Jover R, Llor X, Xicola R. Tu1100: HETEROZYGOUS MUTATIONS IN DNA REPAIR GENES CONFER GENETIC SUSCEPTIILITY TO COLORECTAL CANCER AMONG LYNCH-LIKE CASES. Gastroenterology 2022, 162: s-883. DOI: 10.1016/s0016-5085(22)62088-2.Peer-Reviewed Original ResearchQIM22-192: Mismatch Repair Protein Immunohistochemistry: Quality of Mismatch Repair Deficiency Detection
Matsumoto N, Barbieri A, Gershkovich P, Cecchini M, Gibson J. QIM22-192: Mismatch Repair Protein Immunohistochemistry: Quality of Mismatch Repair Deficiency Detection. Journal Of The National Comprehensive Cancer Network 2022, 20: qim22-192. DOI: 10.6004/jnccn.2021.7192.Peer-Reviewed Original ResearchMutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential
Giner-Calabuig M, De Leon S, Wang J, Fehlmann TD, Ukaegbu C, Gibson J, Alustiza-Fernandez M, Pico MD, Alenda C, Herraiz M, Carrillo-Palau M, Salces I, Reyes J, Ortega SP, Obrador-Hevia A, Cecchini M, Syngal S, Stoffel E, Ellis NA, Sweasy J, Jover R, Llor X, Xicola RM. Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential. British Journal Of Cancer 2022, 126: 1595-1603. PMID: 35197584, PMCID: PMC9130322, DOI: 10.1038/s41416-022-01754-1.Peer-Reviewed Original ResearchConceptsLynch-like syndromeMMR-deficient tumorsLynch syndromeMicrosatellite instabilityPercent of tumorsMSH2/MSH6 expressionColorectal cancer tumorsPMS2 protein expressionMutational signaturesResultsFifty-three percentClinical managementNeoantigen presentationMSH6 expressionHallmark of tumorsTumor behaviorMMR deficiencyClinical phenotypeDeficient tumorsTumorsSporadic tumorsCancer tumorsMutational profileProtein expressionRepair deficiencySyndrome
2021
Pathogenic BRCA2 germline variants in combined hepatocellular‐cholangiocarcinoma
Li H, Zhang X, Finberg KE, Walther Z, Jain D, Gibson J. Pathogenic BRCA2 germline variants in combined hepatocellular‐cholangiocarcinoma. Pathology International 2021, 72: 138-140. PMID: 34808016, DOI: 10.1111/pin.13188.Peer-Reviewed Original ResearchYale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan
Gibson JA, Finberg KE, Nalbantoglu I, Cecchini M, Ganzak A, Walther Z, Sklar JL, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan. The Lancet Oncology 2021, 22: 306-307. PMID: 33662283, DOI: 10.1016/s1470-2045(20)30683-5.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Teaching & Mentoring
Mentoring
Carlos Mauricio Mejia Arbelaez, MD/MPH
Resident2023 - Present
Clinical Care
Overview
Joanna A. Gibson, MD, PhD, a pathologist, still remembers details from a lecture she heard as a graduate teaching assistant in the Mayo Clinic’s MD-PhD program in Rochester, Minn. “I remember the lecturer explained how cancer cells behaved in the body, and then showed an image of those cancer cells within a biopsy sample projected on a slide—and it just clicked for me,” Dr. Gibson says. “I loved how pathology brought the science and the patient care aspects together.” Today, Dr. Gibson specializes in diagnosing gastrointestinal and liver diseases, including cancers, at Yale Medicine.
“For each patient case, I read through the medical history and notes to get a good idea in my mind about who the patient is,” Dr. Gibson says. Even when dealing with a high volume of biopsies, taking these extra moments to put together a patient’s story is crucial, she says.
As an assistant professor of pathology at Yale School of Medicine, Dr. Gibson also conducts research on the pathology of gastrointestinal diseases.
Clinical Specialties
Pathology; Anatomic Pathology; GI & Liver Pathology; Surgical Pathology; Molecular & Genomic Pathology
Fact Sheets
Molecular Diagnostics
Learn More on Yale MedicineHyperthermic Intraperitoneal Chemotherapy (HIPEC)
Learn More on Yale Medicine
Board Certifications
Anatomic & Clinical Pathology
- Certification Organization
- AB of Pathology
- Latest Certification Date
- 2018
- Original Certification Date
- 2008
Yale Medicine News
News
News
- February 23, 2024
Yale Pathology to have Strong Presence at 113th Annual USCAP Meeting
- June 20, 2023
18 Faculty Selected as Inaugural Longitudinal Coaches for MD Students
- May 02, 2022
Yale Pathology Diagnostic Pathology CME Annual Review Scheduled for September 17-18 at Yale Club of NYC
- March 14, 2022
Yale Pathology Joins in Celebration of National Patient Safety Awareness Week